Keywords: ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial
Keywords: ACR; American College of Rheumatology; CRP; C-reactive protein; CTA; computed tomographic angiography; ESR; erythrocyte sedimentation rate; GCA; giant cell arteritis; HbA1C; hemoglobin A1C; MRA; magnetic resonance angiography; PET/CT; positron emission to
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials
Keywords: dyslipidemia; evolocumab; lipoprotein(a); PCSK9Â inhibition; CVD; cardiovascular disease; LDL; low-density lipoprotein; PCSK9; proprotein convertase subtilisin/kexin type 9; Q2W; every 2 weeks; Q4W; every 4 weeks; SC; subcutaneous; UC LDL-C; low-density l
Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients
Keywords: AE; adverse event; alb-IFN; albinterferon alfa-2b; ANC; absolute neutrophil count; BMI; body mass index; CHC; chronic hepatitis C; ETR; end-of-treatment response; Hb; hemoglobin; HOMA-IR; homeostasis model assessment of insulin resistance; IFN; interferon